Last reviewed · How we verify
1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid (CYCLOBUTYROL)
1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid (generic name: CYCLOBUTYROL) is a cyclobutyrol drug. It is currently in Phase 2 development.
Cyclobutyrol is thought to work by interacting with a specific molecular target, although the exact mechanism is not yet fully understood.
1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid, also known as Cyclobutyrol, is a small molecule drug in the cyclobutyrol class. Its mechanism of action and target are currently unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the potential benefits and risks of this compound. Due to its lack of FDA approval and limited information, Cyclobutyrol is not currently available as a prescription medication.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CYCLOBUTYROL |
|---|---|
| Drug class | cyclobutyrol |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and the key to unlocking them is a specific shape that fits perfectly. Cyclobutyrol is like a key that tries to fit into one of these locks, but we don't yet know which lock it's meant for or how it will affect the cell's behavior.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid CI brief — competitive landscape report
- 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid updates RSS · CI watch RSS
Frequently asked questions about 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid
What is 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid?
How does 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid work?
What is the generic name of 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid?
What drug class is 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid in?
What development phase is 1-Hydroxy-Alpha-Ethylcyclohexylacetic Acid in?
Related
- Drug class: All cyclobutyrol drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing